← Back

Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. Its lead candidate, azenosertib, is in a Phase 3 clinical trial for ovarian cancer and other tumor types. The company also conducted a Phase 1 study of azenosertib monotherapy in solid tumors (ZN-c3-001) and a Phase 1/2 trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer (MAMMOTH, ZN-c3-006). Zentalis has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. The company was incorporated in 2014 and is based in San Diego, California.

Country
Price · split & dividend adjusted
News & notes moving ZNTL
ZNTL▼2

Zentalis Pharma Prices $80.5 Million Share Offering at $3.50

Zentalis Pharmaceuticals has priced a public offering of 23 million shares at $3.50 per share, expecting total gross proceeds of $80.5 million. The clinical-stage oncology company plans to use the net proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners, with H.C. Wainwright & Co. as passive bookrunner and Rodman & Renshaw LLC as manager. Zentalis develops treatments for ovarian cancer and multiple tumour types, with lead investigational drug Azenosertib in development for ovarian cancer. The stock closed Thursday at $4.15, down 3.26%, and fell a further 9.16% to $3.77 in overnight trading.
ZNTL ▼
RTTNews·35dRead more →
Biotech & Genomic Medicine▲

Zentalis to present overall survival data for azenosertib in ovarian cancer at ESMO 2026

Zentalis Pharmaceuticals announced it will present overall survival results from the DENALI Part 1b study of its investigational WEE1 inhibitor azenosertib at the European Society for Medical Oncology Congress 2026 in Madrid. The data, accepted as a rapid oral presentation, highlight long-term survival benefits in patients with Cyclin E1-positive platinum-resistant ovarian cancer. The company will also present a trial-in-progress poster on ASPENOVA, a Phase 3 study of azenosertib monotherapy versus standard-of-care chemotherapy in the same biomarker-selected population. DENALI Part 1b enrolled patients regardless of Cyclin E1 expression and treated them with azenosertib at 400 mg once daily on a 5-days-on, 2-days-off schedule. Zentalis is advancing azenosertib in registration-intended monotherapy trials for this high-unmet-need group, which represents approximately 50% of platinum-resistant ovarian cancer patients.
ZNTL ▲
Biotech & Genomic Medicine
GlobeNewswire·63dRead more →
© 2026 MarketDXAsset